Thoracic TumorsNCT06840288
Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry
An observational study of Thoracic Tumors, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thoracic Tumors
- How many people
- 250 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Feb 2025to 31 Dec 2036
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: MD Anderson Cancer Center
Who may be able to join
- Patients with peripheral lung tumors (primary or metastatic) that have been or will be ablated via robotic bronchoscopy.
Who cannot join
- Patients with planned bronchoscopic ablations of peripheral lung tumors that were aborted for technical reasons (ablation was not completed).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
MD Anderson Cancer Center
Houston, Texas, 77030
Roberto F Casal, MD, 713-792-6238, rfcasal@mdanderson.org
About this study
To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.
Read the detailed description
- To aggregate, integrate, and analyze data facilitating the study of patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.
- To assess the intra-operative, peri-operative, and long-term safety outcomes of robotic assisted bronchoscopic ablation of peripheral lung tumors.
- To evaluate different oncologic outcomes including local tumor progression (LTP) by RECIST criteria, local tumor progression free survival (LTPFS), progression free-survival (PFS), disease (cancer) specific survival (DSS), and overall survival (OS).
- To provide a deeper understanding of the evolution of radiographic findings of bronchoscopically ablated lung tumors over time.
- To evaluate tumor and patient-related risk factors that may be associated with safety (bleeding, pneumothorax, and local infection) and oncologic outcomes (LTPFS, PFS, DSS, and OS).
- To explore the role of radiomics in monitoring and predicting ablation response by examining pre and post ablation images (chest CT).
- Conditions
- Thoracic Tumors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Small Thoracic Tumors | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.
Measured: Follow-up will continue per standard of care until death. Data will be collected when available in the patient's chart for a minimum of 5 years and a maximum of 10 years from ablation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2025
- Study start19 Feb 2025
- Primary completion31 Dec 2034 (estimated)
- Study completion31 Dec 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thoracic TumorsStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Roberto F Casal, MD, Principal investigator, Prinicipal Investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06840288
- Sponsor's protocol ID
- 2024-1847
- Other IDs
- NCI-2025-01258
- Status last verified
- Oct 2026
- First submitted
- 17 Feb 2025
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No